Showing 49 - 56 of 8794 results
April 27, 2021 |Podcast |Viewpoint
April 27, 2021 |Blog |Viewpoint
April 27, 2021 |News
April 27, 2021 |Article |Viewpoint
April 23, 2021 |News
April 22, 2021 |News
April 22, 2021 |Blog |Viewpoint
News & Press Releases
In an article published by Law360, Mintz Member and Co-chair of the firm’s Securities Litigation Practice Jack Sylvia was quoted on the contentious legal battle between Massachusetts Secretary of the Commonwealth William Galvin and stock trading and investing app Robinhood, which is poised to test the state’s new fiduciary rule, and, by extension, the authority of one of the most aggressive securities regulators in the country.
Don’t Be Caught Without Possession (of Your Invention): What You Need To Know About the Written Description Requirement
May 12, 2021
Mintz Members Peter Cuomo and Muriel Liberto co-authored an article published in the March/April 2021 issue of IP Litigator that examined how the U.S. written description requirement is developing in the ‘unpredictable’ pharmaceutical and biotechnology-related arts. In their article, Mr. Cuomo and Dr. Liberto reviewed a line of post-Ariad “blaze marks” cases illustrating what may become a trend toward a higher bar for satisfying the written description requirement in the United States, particularly as applied to genus claims covering molecules large and small, such as antibodies, enzymes, and small organic molecules. Where the claim further relies upon functional language to define a genus of compounds, the authors cautioned that the bar is likely to be even higher to the extent this line of cases is followed.